1374P - Analysis of evolution of patient reported side effects during treatment for advanced NSCLC

Background

Lung cancer remains the most lethal cancer worldwide. For NSCLC, novel treatments have improved both the overall survival and patient quality of life, but some side effects persist. This study aims to investigate the evolution of common side effects that present early during treatment.

Methods

SNF-CLIMEDIN is a prospective randomized study with digital intervention in advanced NSCLC patients, conducted by the Hellenic Co-operative Oncology Group (HeCOG). All patients had NGS analysis and received standard of care treatment. They engaged in the CareAcross online platform and received, digitally, material about their disease and treatment.

All patients periodically reported their side effects among a predefined set; half received personalized automated support, digitally, based on their reports.

The analysis focused on side effects reported up to cycle 3, and same-patient reports between cycles 3 & 5, and cycles 5 & 7.

Results

200 patients entered the study between February 2022 and September 2023. Most (66%) received immuno-chemotherapy, 12.5% combination immunotherapy and 10.5% chemotherapy.

The most common side effects reported up to cycle 3 were fatigue, cough, nausea, anorexia, constipation and weight loss.

The table shows the number of patients who reported each side effect up to treatment cycle 3, followed by reports by the same patients up to cycles 5 and 7.

Cough, nausea, anorexia, constipation and weight loss initially reported, and improved before cycle 5, generally did not reappear before cycle 7. On the contrary, if fatigue was initially reported and subsequently improved, it reappeared in 47% of the patients before cycle 7.

Conclusions

In this Patient Reported Side effects analysis, cough, nausea, anorexia, constipation, weight loss do not relapse after improvement. On the contrary, fatigue reappears more often after a temporary improvement. Such insights, combined with clinical assessment, can help clinicians better prioritize support. Table: 1374P

Clinical trial identification

NCT05372081.

Editorial acknowledgement

Legal entity responsible for the study

Hellenic Co-operative Oncology Group.

Funding

Stavros Niarchos Foundation.

Disclosure

H. Linardou: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Roche, BMS/Pfizer, Pfizer, Novartis, MSD Oncology, Amgen; Financial Interests, Personal, Advisory Role: Pfizer, Roche, MSD Oncology, BMS/Pfizer, AstraZeneca, GSK; Other, Personal, Other, Travel, Accommodation, Expenses: Pfizer Hellas. T. Kosmidis: Financial Interests, Personal, Full or part-time Employment: CareAcross digital health company; Financial Interests, Personal, Stocks or ownership: CareAcross digital health company; Financial Interests, Personal, Leadership Role: CareAcross digital health company. A. Vozikis: Financial Interests, Institutional, Research Funding: BMS, Roche, Takeda, MSD, Novo Nordisk. A. Psyrri: Financial Interests, Personal, Invited Speaker: MSD, Merck Serono, EPICS; Financial Interests, Personal, Advisory Board: Pfizer, Sanofi, MSD, AstraZeneca, BMS, LEO, RAKUTEN, eTheRNA immunotherapies, Merck Serono, Seagen, Merus, Merus Pharmaceuticals, GSK; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Pfizer, GSK, Genesis, Incyte, Amgen, Debiopharm, MSD, Janssen, Lilly, Regeneron, Sanofi, BI, Roche, Peregrine, Oncolytics Biotech; Financial Interests, Coordinating PI: AstraZeneca; Financial Interests, Personal and Institutional, Steering Committee Member: Iovance, Pfizer, Roche; Financial Interests, Institutional, Steering Committee Member: Kura Oncology; Financial Interests, Steering Committee Member: Kura Oncology; Financial Interests, Personal and Institutional, Funding: Kura Oncology, BMS, Roche, DEMO, Amgen, BI, GENESIS, BMS, Pfizer, Oncolytics Biotech; Financial Interests, Institutional, Funding: Merck Serono, Pfizer, GSK; Financial Interests, Personal, Other, Educational activity: Medscape, prIME Oncology; Financial Interests, Institutional, Local PI: Novartis, Replimmune; Financial Interests, Personal, Steering Committee Member: GSK, Merus pharmaceuticals. E. Fountzilas: Financial Interests, Personal, Invited Speaker: Gilead; Financial Interests, Personal, Stocks/Shares: Deciphera, Genprex; Other, Conference: Genesis, AstraZeneca, KAM. A.N. Christopoulou: Financial Interests, Personal, Other, Honoraria: AstraZeneca, BMS, MSD, GSK, Servier; Financial Interests, Personal, Advisory Role: AstraZeneca, MSD, Servier. E. Samantas: Financial Interests, Personal, Other, Honoraria: Amgen, MSD, AstraZeneca; Financial Interests, Personal, Advisory Role: Amgen, MSD, AstraZeneca, Bristol Myers Squibb. A. Vagionas: Financial Interests, Personal, Other, Honoraria: Amgen, Roche, BMS GmbH & Co. KG, MSD; Financial Interests, Personal, Advisory Role: Roche, Lilly, Merck Serono, Pierre Fabre; Other, Personal, Other, Travel, Accommodation, Expenses: Roche. G. Mountzios: Financial Interests, Personal, Other, Honoraria: Roche, Boehringer Ingelheim, AstraZeneca, MSD, BMS GmbH & Co. KG, Novartis, Amgen, Takeda; Financial Interests, Personal, Advisory Role: Roche, AstraZeneca/Greece, MSD, Amgen, Novartis, BMS GmbH & Co. KG, Takeda; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Other, Personal, Other, Travel, Accommodation, Expenses: AstraZeneca, Ipsen, MSD, Roche, Novartis, BMS GmbH & Co. KG, Demo Pharmaceutical. N.G. Tsoukalas: Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Speaker’s Bureau: Merck, Roche; Financial Interests, Personal, Research Funding: Gilead, LEO Pharma, Merck; Other, Personal, Other, Travel, Accommodation, Expenses: Ipsen, Teva, LEO Pharma. I. Athanasiadis: Financial Interests, Personal, Invited Speaker, 1) Participation in the ''11TH Multidisciplinary Care Discussions In Oncology'' 11/11/23 Divani Caravel, 2) Participation in Satellite Lecture "9th Panhellenic Congress of the Hellenic Society of Breast Surgery” 26/11/2023 Royal Olympic, 3) Participation in the 10TH Multidisciplinary Care Discussions in Oncology 11- 12 November 2022, 4) Speaker at the scientific event entitled: AstraZeneca S.A.; Financial Interests, Personal, Invited Speaker, Speaker at the Scientific Event entitled ''Endocrine Resistance in ER+, HER2 - Metastatic Breast Cancer'' Held 1/11/23: Integris Pharma ΑΕ; Financial Interests, Personal, Advisory Board, 1)Advisory Board Titled ''Group Input Meeting on Current Landscape & Future Perspectives in Gl and Early-Stage NSCLC'', 2) Speaker at the National Conference on ''Multidisciplinary Approach to Cancer'' Held on 23/11/23-25/11/23 in Athens, 3) Speaker at the Educational Meeting on ''Fireside Chat: Immuno-Oncology Updates in Solid Tumors'' Organized BY MSD IN Athens 21/6/23, 4) Participation in the Advisory Committee for the Vaccines Sector Meeting 08/06/2022, 5) Coordinator- Speaker at the Medical Training Programme Held in ATHENS 23/6/22, 6) 12TH National Conference on Oncology in the Daily Practice 6-9/10/22, 7)Consultancy Services in the Framework of the Expert Committee Advisory Board Meeting 24/11/21: Merck Sharp and Dohme; Financial Interests, Personal, Writing Engagement, Participation in MSD'S IO-Horizon Study and Completion of Electronic Case Recording Forms: Quolitis Consulting Research Ltd.; Financial Interests, Personal, Invited Speaker, Speaker at the event entitled ''11th Multidisciplinary Care Discussions in Oncology'' on ''Optimal Treatment of BRAF Positive Metastatic Colorectal Cancer''' Held at the Divani Caravel in Athens on 10/11/23: Pierre Fabre Farmaka Anonymous Trade Company; Financial Interests, Personal, Invited Speaker, 1) Speech 11/2/23 IN Event, 2) Speaker at the 10TH Multidisciplinary Care Discussions in Oncology MDCON 2022: Roche Hellas SA; Financial Interests, Personal, Invited Speaker, Speaker at the Event: Specifar SA Chemical and Pharmaceutical Products Industry; Financial Interests, Personal, Invited Speaker, 1) Novartis' Website Lecture on 7/10/23 at the 13th International Conference Oncology: Novartis Hellas AVE. Financial Interests, Personal, Invited Speaker, 1) Speaker at the Satellite Lecture Entitled ''Emerging Role of KRS G12C Mutation as a New Druggable Biomarker'' Held on 22/10/21 at the Athenium Intercontinental, 2) Participation as Advisor to the Advisory Board Sotorasib HTA Strategy & Dossier Preparation on 9/12/21: Amgen Ellas Pharmacetics Ltd.; Financial Interests, Personal, Invited Speaker, Participation in GSK Advisory Meeting on ''Identifying the Challenges and the Opportunities for Dostarlimab within the Context of the Current Clinical Practice of the Recurrent Endometrial Cancer in Greece'' ON 10/12/21: GSK S.A.; Financial Interests, Personal, Invited Speaker, Invited Speaker, Specifar Company's Interview with Video Oncology Issues Held in Athens on 13/4/22: Pharmabide Pharmaceutical Businesses Limited Liability Company; Financial Interests, Personal, Invited Speaker, Consultancy services in the framework of a Consultancy Meeting on: Genesis Farma Anonymous Pharmaceutical Company; Financial Interests, Personal, Invited Speaker, 1)Participation in the event "Questions and answers in the management of patients with metastatic triple-negative breast-cancer (mTNBC)” on 18/11/2022 in the framework of the "Conference of Clinical and Metastatic Oncology 2022: Gilead Sciences Hellas Monoporos Ltd.; Financial Interests, Personal, Invited Speaker, Invited Speaker, Speaker at the company's Forward Lecture at the 6TH Greek Conference Oncology Meeting Held IN Thessaloniki 4-7/5/22: Pharmaserv-Lilly S.A.; Financial Interests, Personal, Invited Speaker, Scientific Lecture on the Subject: ''Debates on Prostate Cancer Treatment'': Janssen-Cilag Pharmaceuticals S.R.O. ; Financial Interests, Personal, Member of Board of Directors, Epistimoniki and Ekpaydeitiki Ogkologiki Etaipeia: Scientific Educational Ogological Society; Financial Interests, Institutional, Officer, Scientific Responsibility of Mithera S.A. Daily Treatment Unit: Mitera SA; Financial Interests, Personal, Ownership Interest, President: Scientific Educational Oncological Association Differently Interested in Oncological Societies; Financial Interests, Personal, Ownership Interest, President: Scientific Educational Oncological Association? Non-Financial Interests, Other, Principal Researcher of his Center in Studies: HeCOG? Non-Financial Interests, Institutional, Other, Biological Material from Patients for Inclusion in a Study with Free Inspection: HeCOG. C.G. Panopoulos: Financial Interests, Personal, Other, Honoraria: AstraZeneca. M.I. Koufaki: Financial Interests, Personal, Full or part-time Employment: Icon plc. G. Fountzilas: Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Stocks/Shares: Genprex, Daiichi Sankyo, Rafael Holdings, Formycon; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Novartis. P.A. Kosmidis: Financial Interests, Personal, Other, Travel, Accommodation, Expenses: Pfizer Hellas, AstraZeneca Greece; Financial Interests, Personal, Ownership Interest: CareAcross Digital Health Company; Non-Financial Interests, Leadership Role, Chief Medical Officer: CareAcross Digital Health company. All other authors have declared no conflicts of interest.